Eldridge Investment Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,510
| Closed | -$211K | – | 167 |
|
|
2026
Q1 | $211K | Buy |
+7,510
| New | +$200K | 0.05% | 149 |
|
|
2025
Q4 | – | Sell |
-11,310
| Closed | -$288K | – | 163 |
|
|
2025
Q3 | $288K | Sell |
11,310
-150
| -1% | -$3.7K | 0.07% | 138 |
|
|
2025
Q2 | $278K | Sell |
11,460
-450
| -4% | -$10.5K | 0.06% | 139 |
|
|
2025
Q1 | $302K | Sell |
11,910
-250
| -2% | -$6.54K | 0.07% | 135 |
|
|
2024
Q4 | $323K | Sell |
12,160
-243
| -2% | -$6.59K | 0.08% | 131 |
|
|
2024
Q3 | $359K | Buy |
12,403
+486
| +4% | +$14.2K | 0.08% | 123 |
|
|
2024
Q2 | $333K | Buy |
11,917
+1,677
| +16% | +$46.2K | 0.08% | 121 |
|
|
2024
Q1 | $284K | Buy |
10,240
+701
| +7% | +$19.5K | 0.07% | 131 |
|
|
2023
Q4 | $275K | Hold |
9,539
| – | – | 0.07% | 128 |
|
|
2023
Q3 | $316K | Sell |
9,539
-286
| -3% | -$10.1K | 0.1% | 109 |
|
|
2023
Q2 | $360K | Hold |
9,825
| – | – | 0.12% | 105 |
|
|
2023
Q1 | $401K | Buy |
9,825
+1
| +0% | +$43 | 0.14% | 95 |
|
|
2022
Q4 | $503K | Hold |
9,824
| – | – | 0.18% | 76 |
|
|
2022
Q3 | $430K | Sell |
9,824
-1
| -0% | -$49 | 0.17% | 83 |
|
|
2022
Q2 | $515K | Hold |
9,825
| – | – | 0.19% | 68 |
|
|
2022
Q1 | $509K | Buy |
9,825
+3
| +0% | +$156 | 0.17% | 74 |
|
|
2021
Q4 | $580K | Buy |
9,822
+1
| +0% | +$50 | 0.19% | 67 |
|
|
2021
Q3 | $422K | Buy |
9,821
+145
| +1% | +$6.42K | 0.15% | 79 |
|
|
2021
Q2 | $379K | Buy |
9,676
+3
| +0% | +$117 | 0.14% | 80 |
|
|
2021
Q1 | $350K | Buy |
9,673
+145
| +2% | +$5.15K | 0.14% | 84 |
|
|
2020
Q4 | $351K | Sell |
9,528
-511
| -5% | -$18.7K | 0.15% | 77 |
|
|
2020
Q3 | $350K | Sell |
10,039
-402
| -4% | -$14.1K | 0.16% | 69 |
|
|
2020
Q2 | $324K | Buy |
10,441
+37
| +0.4% | +$1.26K | 0.16% | 72 |
|
|
2020
Q1 | $322K | Buy |
10,404
+3
| +0% | +$102 | 0.18% | 65 |
|
|
2019
Q4 | $387K | Buy |
10,401
+2
| +0% | +$71 | 0.19% | 65 |
|
|
2019
Q3 | $354K | Sell |
10,399
-94
| -0.9% | -$3.42K | 0.18% | 64 |
|
|
2019
Q2 | $431K | Buy |
10,493
+3
| +0% | +$119 | 0.23% | 56 |
|
|
2019
Q1 | $423K | Buy |
10,490
+2,626
| +33% | +$105K | 0.23% | 54 |
|
|
2018
Q4 | $326K | Buy |
7,864
+197
| +3% | +$8.18K | 0.2% | 57 |
|
|
2018
Q3 | $320K | Buy |
7,667
+598
| +8% | +$23K | 0.2% | 50 |
|
|
2018
Q2 | $243K | Sell |
7,069
-168
| -2% | -$5.74K | 0.17% | 55 |
|
|
2018
Q1 | $243K | Buy |
+7,237
| New | +$249K | 0.18% | 53 |
|
Other funds holding PFE
Eldridge Investment Advisors's PFE Position: Q2 2026 in Review
Eldridge Investment Advisors sold out of Pfizer (PFE) in Q2 2026, closing a stake of 7,510 shares — an estimated $211K sold.
Eldridge Investment Advisors first reported a position in PFE in Q1 2018 and held it in 32 quarters. The position peaked at $580K in Q4 2021. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Eldridge Investment Advisors reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
- Eldridge Investment Advisors sold 7,510 Pfizer shares in Q2 2026, an estimated $211K.
- Eldridge Investment Advisors first reported a position in Pfizer in Q1 2018 and held it in 32 quarters.
- Eldridge Investment Advisors's Pfizer position peaked at $580K in Q4 2021.
- 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Eldridge Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.